Europe Medical Cannabis Market Overview 

Market Size in 2024: USD 2,586.1 Million

Market Forecast in 2033: USD 12,652.9 Million

Market Growth Rate: 18.33% (2025-2033)

According to the latest report by IMARC Group, the Europe medical cannabis market size was valued at USD 2,586.1 Million in 2024. Looking ahead, IMARC Group estimates the medical cannabis size in market to reach USD 12,652.9 Million by 2033, exhibiting a CAGR of 18.33% from 2025 to 2033.

Europe Medical Cannabis Industry Trends and Drivers:

Driven by extensive legal changes, growing public acceptance, and the growing clinical use of cannabinoid-based medicines, the European medical cannabis market is now moving quickly. Healthcare experts and patients are increasingly seeing medical cannabis as a realistic therapy choice for chronic pain, neurological diseases, and oncology-related conditions as more nations are accepting regulatory systems supporting it. Growing interest in non-opioid pain alleviation and plant-based medicine is changing treatment choices among different groups. At the same time, pharmaceutical companies and biotechnology companies are increasing research and development projects to investigate novel formulations, boost bioavailability, and guarantee dosage delivery consistency. These developments are encouraging creativity in cannabis derivatives—most notably cannabidiol (CBD) and tetrahydrocannabinol (THC) extracts—which are being customized to satisfy a wide range of therapeutic needs. The growing use of oral solutions, capsules, and vapour-delivery systems is further bolstering a user-centric change in customized medicine.

Driven by a sophisticated healthcare system, extensive physician involvement, and a well-built reimbursement mechanism, Germany is still leading the regional medical cannabis scene. Driven by an expanding body of clinical evidence and government backing of medicinal cannabis use, the nation is seeing more cannabis-based drugs prescribed. This nurturing environment is persuading foreign and local businesses to put funds toward cultivating infrastructure, local manufacturing, and distribution networks. Concurrently, developments in hydroponic agriculture and greenhouse automation are increasing crop output, while extraction techniques are changing to guarantee greater purity and product standardization. Simultaneously, strategic partnerships between licensed producers and research institutions are quickening the creation of new delivery methods, including sublingual sprays and transdermal patches, thereby improving patient adherence and enlarging application possibilities over diseases like anxiety, epilepsy, and multiple sclerosis.

Outside Germany, progressive medical cannabis laws and increasing clinical trials activity make the Netherlands, Italy, and Portugal also important markets. With politicians progressively matching public health goals with patient advocacy, these areas are seeing marijuana as a vital element of integrative treatment. Manufacturers are expanding operations and adding both species—Cannabis sativa and Cannabis indica—to meet growing demand so prescribers may customize treatment regimens based on individual patient needs. Hospitals, specialized clinics, and pharmacies are implementing standardized distribution models, thereby guaranteeing controlled access and trackable supply chains. With increasing focus on quality assurance, safety procedures, and digital prescription platforms, the Europe medical cannabis market is entering a transformative stage that presents long-term growth prospects for stakeholders dedicated to innovation, compliance, and therapeutic excellence.

Download sample copy of the Report: https://www.imarcgroup.com/europe-medical-cannabis-market/requestsample

Europe Medical Cannabis Industry Segmentation:

The report has segmented the market into the following categories:

Analysis by Species:

• Indica
• Sativa
• Hybrid

Analysis by Derivative:

• Cannabidiol (CBD)
• Tetrahydrocannabinol (THC)
• Others

Analysis by Application:

• Cancer
• Arthritis
• Migraine
• Epilepsy
• Others

Analysis by End Use:

• Pharmaceutical Industry
• Research and Development Centers
• Others

Analysis by Route of Administration:

• Oral Solutions and Capsules
• Smoking
• Vaporizers
• Topicals
• Others

Analysis by Country:

• Germany
• France
• United Kingdom
• Italy
• Spain
• Others

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Latest News and Developments:

• May 2025: Curaleaf International, in partnership with Jupiter Research LLC, obtained regulatory authorization for a portable liquid inhaler intended for accurate delivery of medical cannabis. This EU medical device approval will unlock opportunities for a new age technological advancement in medical cannabis administration, providing patients with better solutions.
• April 2025: Aurora Cannabis launched its first inhalable resin cartridges for medical patients in the UK, introducing two proprietary 1.2g strains - Sourdough (indica) and Electric Honeydew (sativa). These cartridges offer fast-acting, high-potency, and discreet delivery, manufactured in TGA-GMP certified facilities without additives.
• March 2025: Tilray medicinal announced the launch of Tilray Craft, a new brand addition to Tilray Medical's medical cannabis line, in Germany. With this launch, the company seeks to provide distinctive flower selections that are currently inaccessible in the market, primarily focusing on individuals who need medicinal cannabis flowers with higher THC and terpene content developed from innovative genetic lineages.
• February 2025: Canopy Growth Corporation launched its Tweed brand in the medical cannabis sector in Germany. This includes four new Tweed strains that are grown in the EU courtesy of a partnership with the Portuguese medicinal cannabis grower Gro-Vida S.A. (Gro-Vida).
• January 2025: Aurora Cannabis Inc. reported the release of its first medical cannabis product grown in Germany, under the company’s IndiMed brand. Developed at Aurora's EU-GMP plant in Leuna, the newly launched brand provides the nation's growing patient base with a source of premium, locally cultivated and distributed medical cannabis.
• February 2024: Tikun Olam Europe became the first company to offer medical cannabis products under prescription in Greece. The company plans to introduce new products soon and aims to set a benchmark for the industry. Tikun Olam Europe is leveraging Greece's advantages, such as lower costs, a favorable climate for cultivation, and skilled pharmaceutical experts.

Key highlights of the Report:

• Market Performance (2019-2024)
• Market Outlook (2025-2033)
• COVID-19 Impact on the Market
• Porter’s Five Forces Analysis
• Strategic Recommendations
• Historical, Current and Future Market Trends
• Market Drivers and Success Factors
• SWOT Analysis
• Structure of the Market
• Value Chain Analysis
• Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

Ask analyst for your customized sample: https://www.imarcgroup.com/request?type=report&id=3059&flag=C

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:  

IMARC Group 

134 N 4th St. Brooklyn, NY 11249, USA 

Email: sales@imarcgroup.com 

Tel No:(D) +91 120 433 0800 

United States: +1-631-791-1145